arrow
T

Todd Wisialowski

Pfizer
H指数:20
被引数:1,277

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reevaluating safety pharmacology respiratory studies within the ICH S7A core battery: A multi-company evaluation of preclinical utility and clinical translation

重新评估ICH S7A核心组中的安全性药理学呼吸研究:一项多公司评估,评估其非临床效用和临床转化

2025-09-010
PRE
Characterization of vasoactive agents in a canine safety pharmacology PKPD model: A HESI initiative

血管活性剂在犬安全性药理学PKPD模型中的表征:一项HESI倡议

2025-09-010
PRE
Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As (vol 123, 107270, 2023)

非啮齿类动物非临床在体心血管遥测研究最佳实践考量:提供高质量QTc数据以支持ICH E14/S7B答疑(卷123,107270,2023)

2025-09-010
OAAI
Reevaluating safety pharmacology respiratory studies within the ICH S7A core battery: A multi-company evaluation of preclinical utility and clinical translation

重新评估ICH S7A核心电池内的安全药理学呼吸研究: 临床前效用和临床翻译的多公司评估

2024-11-010
PRE
Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™
2022-05-2114
OA
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective
2020-09-2468
OAAI
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
2019-11-1065
OAAI